Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.40

0.0%

Nov 28 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (927)	6/11/2001 7:29:14 AM
From: nigel bates	Read Replies (2) of 1475

HARLESTOWN, Mass., June 11 /PRNewswire/ -- BioTransplant Incorporated (Nasdaq: BTRN - news) today announced the completion of a $19.0 million private placement of approximately 3,022,457 shares of newly issued common stock, at a purchase price of $6.30 per share, to selected institutional and accredited investors. The Company intends to use the aggregate net proceeds from the private placement of approximately $17.9 million, to advance the Company's immune modulation therapy programs encompassing the clinical development of its AlloMune(TM) family of product candidates, the expansion of development and commercialization of its Eligix Cell Separation System and to provide it with working capital for other general corporate purposes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next